StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.50+0.04 (+1.16%)

Close on Nov 18, 2026Market cap $226.67MP/E –Yield –

Immuneering net income

Net income is the profit left for shareholders after every expense, interest and tax.

Immuneering's net income for the twelve months ending Sep 30, 2026 was -$66.50M. For fiscal 2025 it was -$56.02M. The highest annual figure on record is -$17.04M in fiscal 2020.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$56.02M–
FY2024Dec 31, 2024-$61.04M–
FY2023Dec 31, 2023-$53.47M–
FY2022Dec 31, 2022-$50.51M–
FY2021Dec 31, 2021-$33.54M–
FY2020Dec 31, 2020-$17.04M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$24.19M–
Q2 FY2026Jun 30, 2026-$17.27M–
Q1 FY2026Mar 31, 2026-$13.46M–
Q4 FY2025Dec 31, 2025-$11.58M–
Q3 FY2025Sep 30, 2025-$14.96M–
Q2 FY2025Jun 30, 2025-$14.43M–
Q1 FY2025Mar 31, 2025-$15.05M–
Q4 FY2024Dec 31, 2024-$18.05M–
Q3 FY2024Sep 30, 2024-$14.60M–
Q2 FY2024Jun 30, 2024-$14.08M–
Q1 FY2024Mar 31, 2024-$14.31M–
Q4 FY2023Dec 31, 2023-$15.08M–
Q3 FY2023Sep 30, 2023-$12.60M–
Q2 FY2023Jun 30, 2023-$12.19M–
Q1 FY2023Mar 31, 2023-$13.60M–
Q4 FY2022Dec 31, 2022-$13.25M–
Q3 FY2022Sep 30, 2022-$12.84M–
Q2 FY2022Jun 30, 2022-$11.53M–
Q1 FY2022Mar 31, 2022-$12.90M–
Q4 FY2021Dec 31, 2021-$10.78M–
Q3 FY2021Sep 30, 2021-$8.53M–
Q2 FY2021Jun 30, 2021-$7.99M–
Q1 FY2021Mar 31, 2021-$6.23M–
Q4 FY2020Dec 31, 2020-$5.84M–
Q3 FY2020Sep 30, 2020-$4.40M–
Q2 FY2020Jun 30, 2020-$3.60M–
Q1 FY2020Mar 31, 2020-$3.20M–

More Immuneering figures

See a number that looks wrong?